Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EMP405
- Development stage
- Preclinical
- Lead developer
- Empiriko
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
EMP405 is a preclinical-stage somatostatin receptor (SSTR)-targeted radioligand therapy being developed by Empiriko for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug utilizes Empiriko's proprietary RCV (azamacrocycle carrier) platform to deliver the lutetium-177 (177Lu) radioisotope to tumor cells expressing SSTR. Its unique mechanism of action involves the RCV carrier functioning as a co-drug that amplifies therapeutic efficacy by generating oxidative damage via singlet oxygen radicals, complementing the beta radiation emitted by the 177Lu isotope. This dual-action approach is designed to enhance the anti-tumor effect compared to traditional radioligand therapies.
- Other names
- EMP405-Empiriko-SSTR-radioligand therapy (RCV + 177Lu)-GEP-NETs
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on EMP405.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EMP405.